JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence - Top-Institutions - MDSpire

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • By

  • Zhiying Wu

  • Li Jiang

  • Xu Zheng

  • Wanlin Zhou

  • Zuofeng Wang

  • Weilin Xie

  • July 1, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine / Stanford Health Care–Stanford Hospital
    Stanford University School of Medicine / Stanford Health Care–Stanford Hospital

    Stanford, California

    Key Differentiators

    • Rheumatology

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Rheumatology

Original Source(s)

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

  • by Zhiying Wu, Li Jiang, Xu Zheng, Wanlin Zhou, Zuofeng Wang, Weilin Xie

  • July 1, 2026

Related Content

Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report

CT radiomics with transfer learning features for detecting DECT−positive periarticular monosodium urate crystal deposition: a single−center retrospective study

Gout May Signal Higher Stroke Risk in AF

In a nationwide Finnish cohort, patients with atrial fibrillation and gout had higher ischemic stroke rates, while urate-lowering therapy was associated with lower stroke rates.